Search
Tingsheng Technology has successfully raised approximately 100 million yuan in its Series B+ funding round, led by Yifeng Capital and joined by Qiming Venture Partners and Huangpu Pharmaceutical Fund. The procured funds will be strategically allocated to expedite the research and development (R&D) as well as the clinical implementation of 4D Intracardiac Echocardiography (4D ICE) technology, fostering its mass production. Notably, Tingsheng Technology has previously accomplished China's maiden 4D ICE human clinical trial, signifying a pivotal leap for Chinese enterprises in the global cardiovascular interventional imaging arena. This achievement signifies a shift from mere followers to competitive runners, underscoring the sophistication and maturity of its independent innovation system within the 4D ICE domain.
-
C114 Communication Network -
Communication Home
